News Coverage of Pharmaceutical Patent Settlements
Given all the attention given to Plavix right now, I am surprised there is only one story about modafinil (according to a Google News search).
Mylan Laboratories Inc. (MYL) said Monday that the Federal Trade Commission is investigating the company’s patent-litigation settlement related to the sleep-disorder drug modafinil. As reported earlier this month, Cephalon Inc. (CEPH) entered an agreement related to patent-infringement litigation with Mylan Laboratories, granting Mylan Laboratories non-exclusive, royalty-bearing rights to market and sell the drug in the U.S. Cephalon also entered separate agreements with Teva Pharmaceuticals USA Inc. (TEVA), Ranbaxy Pharmaceuticals Inc. and Barr Laboratories Inc. (BRL). According to Mylan Laboratories’ quarterly report filed Friday with the Securities and Exchange Commission, the FTC requested information from the company and certain subsidiaries related to the patent litigation and settlement with Cephalon in a letter dated July 11.
Technorati Tags: antitrust
RSS Feed
